# PAQ Therapeutics to Present First Clinical Data for PT0253, a Selective KRAS G12D Degrader, in Late-Breaking Oral Presentation at the 2026 EORTC-NCI-AACR Symposium

- Source: PR Newswire M&A
- Published: 2026-11-03T12:00:00+00:00
- Category: Business
- Original: https://www.prnewswire.com/news-releases/paq-therapeutics-to-present-first-clinical-data-for-pt0253-a-selective-kras-g12d-degrader-in-late-breaking-oral-presentation-at-the-2026-eortc-nci-aacr-symposium-302925588.html
- Canonical: https://groundlevelnews.com/story/paq-therapeutics-to-present-first-clinical-data-for-pt0253-a-selective-7c805a/

Presentation to highlight the initial safety profile and antitumor activity of PT0253 in advanced solid tumors, including in patients who received prior (K)RAS-targeted therapy BURLINGTON, Mass., Nov. 3, 2026 /PRNewswire/ -- PAQ Therapeutics, a clinical-stage biotechnology company...

_Ground Level News shows a short summary only; the full article and all rights belong to PR Newswire M&A._